Thus, FLT3-ITD-mutated AML patients with ITD IS in TKD1-sole had a significantly inferior 4-year OS compared with JMD-sole or JMD/TKD1 (p = 0.032). This evidence concerns the gene FLT3 and acute myeloid leukemia.